Editorial

Oxygenating the way for enhanced chemophototherapy

Wen Jiang¹, Ian Michael Delahunty⁴, Jin Xie¹,²

¹. Department of Chemistry, University of Georgia, Athens, GA 30602, USA
². Bio-Imaging Research Center, University of Georgia, Athens, GA 30602, USA

Corresponding author: jinxie@uga.edu

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2018.06.11; Accepted: 2018.06.11; Published: 2018.06.21

Abstract

Hypoxia is behind tumor resistance in both chemotherapy and photodynamic therapy. This editorial highlights a study by Cai et al. [12] that a hemoglobin and human serum albumin hybrid protein nanoparticle can simultaneously deliver O₂, chemotherapeutics, and photosensitizers to tumors for enhanced chemophototherapy.

Key words: hypoxia, photodynamic therapy, chemotherapy, nanoparticles

The combination of chemotherapy and photodynamic therapy (PDT), or chemophototherapy (CPT), is a newly emerging concept [1, 2]. On the one hand, chemotherapy can sensitize cancer cells to PDT and/or kill cancer cells that survived from incomplete PDT. On the other hand, PDT can be utilized to enhance chemotherapeutic drug (often in the form of a nanoparticle) deposition or penetration in tumors. However, the efficacy of CPT is limited by tumor hypoxia, a result of rapid oxygen consumption by cancer cells and insufficient vascular supply [1, 3, 4]. Hypoxia is associated with increased resistance to chemotherapy, inducing hypoxia-inducible factor (HIF-1α) that in turn activates multi-drug resistance protein 1 (MDR1) and mediates the efflux of a wide range of chemotherapeutic drugs [5, 6]. Hypoxia also affects PDT, in which toxicity is produced when a photo-activated photosensitizer transfers electrons to oxygen molecules [1].

Despite extensive research, delivering oxygen to tumors to reverse the course of hypoxia remains a challenge. Conventional methods such as hyperbaric oxygen chambers have been tested in the clinic but have shown limited benefits for tumor oxygenation [4, 7]; rather, increased oxygen blood levels may cause oxygen toxicity to the lungs and the central nervous system [8]. Recently, nanoparticle-based oxygen carriers [9] or generators [10, 11] have been developed and tested. Unlike conventional oxygen delivery, these nanoparticles can selectively accumulate in tumors through either active or passive targeting approaches, and then release oxygen in situ. To maximize therapeutic efficacy, it is reasoned that photosensitizers and chemotherapeutics should be loaded onto the same nanoplatform as the oxygen carrier. This brings additional requirements in design and fabrication of the nanoparticles.

A recent study by Prof. Lintao Cai and his colleagues reports a novel, hybrid protein-oxygen carrier (HPOC) approach to address this aforementioned need [12]. The hybrid consists of two natural proteins, hemoglobin (Hb) and human serum albumin (HSA), which are linked together through a disulfide-bond reconfiguration strategy. Hb is the major oxygen carrier in mammals [9, 13], but has a short blood circulation half-life if administrated alone [14]. Linked with HSA and assembled into a nanoparticle improves the pharmacokinetics of Hb and its accumulation in tumors. Meanwhile, HSA nanoparticles have proven to be an excellent carrier for small molecule drugs, including many types of chemotherapeutics and photosensitizers [15, 16]. In this study, Cai et al. loaded oxygen (by binding with Hb), doxorubicin (DOX), and chlorin e6 (Ce6, a photosensitizer) onto the hybrid protein to form a 30 nm nanoparticle referred to as ODC-HPOC. They
showed that oxygen molecules could be slowly released from the nanoparticles. Incubation with ODC-HPOC reversed cell P-glycoprotein (P-gp) upregulation under hypoxic stress. This led to reduced drug efflux, which was confirmed in a cell uptake study performed in a low oxygen chamber with ODC-HPOC, finding increased intracellular DOX and Ce6 contents relative to the control. They also observed enhanced cell killing under photothermolysis where ODC-HPOC were incubated with MCF-7 cells in a low oxygen chamber. It is expected that the same or greater treatment benefits would be seen in vivo since continuous PDT often exacerbates hypoxia.

The group also evaluated the nanoplatform in vivo in a MCF-7 xenograft model. They found improved tumor accumulation of ODC-HPOCs relative to free DOX or Ce6, which is probably attributed to the enhanced permeability and retention (EPR) effect. Moreover, HSA may have bound with 60-kDa glycoprotein (gp60) receptors, leading to improved nanoparticle transcytosis at tumor sites [17, 18]. Once inside the tumors, oxygen is slowly released from ODC-HPOCs and populates the tumor tissues. Photoacoustic imaging found a 25% increase in HbO2 signals in tumors in ODC-HPOC injected mice, and the impact lasted for hours. The improved drug delivery, drug retention, and oxygenation led to significantly enhanced treatment outcomes. A single dose treatment caused 89.5% tumor suppression, without inducing systemic toxicity.

Hypoxia has long been a target in cancer therapy but selective oxygen delivery to tumors is non-trivial [3]. Compared with inorganic nanoparticle-based oxygen suppliers [10, 11], a hemoglobin containing protein particle certainly has its advantages regarding toxicity and biodegradability. Coupling with HSA to improve the pharmacokinetics of Hb is both novel and clinically relevant. The resulting nanoparticles are function intensive but the components seem to be well integrated with minimal inter-species interference. The compact size is beneficial from delivery and tissue penetration perspectives. It is believed that the nanoplatform can be extended to other chemotherapeutics or even a group of them, which may further enhance treatment efficacy or precision.

Despite these promises, several questions need to be addressed before moving the technology forward. For instance, the nanoplatform essentially delivers three agents (oxygen, chemotherapeutic, and photosensitizer) that play different roles in the combination therapy. It is not clear what the best ratio among these agents is with regard to treatment outcomes. Moreover, it is observed that Abraxane, a paclitaxel-bound HSA nanoparticle, is rapidly disassociated in the blood circulation [17]. Whether this happens to ODC-HPOCs and how this affects drug delivery and therapy remain to be investigated. Additionally, it will be interesting to explore the nanoparticles in the context of other treatment modalities such as radiochemotherapy or even immunotherapy. Overall, this highly innovative approach represents an excellent example of nanoparticle-enabled multifunctional therapeutics and should be of interest to many readers of Theranostics.

Acknowledgements

We thank the National Institutes of Health (R01EB022596 and R01NS093314), the Congressionally Directed Medical Research Program (CA140666), and the National Science Foundation (NSF1552617) for the funding support.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Luo DD, Carter KA, Miranda D, et al. Chemophototherapy: An Emerging Treatment Option for Solid Tumors. Adv Sci, 2017; 4:1-24.
2. Chibber S, Farhan M, Hassan I, et al. Novel aspect of chemophototherapy in treatment of cancer. Tumor Biol, 2012; 33: 701-706.
3. Khoshinani HM, Afshar S, Najafi R. Hypoxia: A Double-Edged Sword in Cancer Therapy. Cancer Invest, 2016; 34: 536-545.
4. Brown JM, William WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer, 2004; 4: 437-447.
5. Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res, 2002; 62: 3387-3394.
6. Samanta D, Gilkes DM, Chaturvedi P, et al. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci USA, 2014; 111: E5429-5438.
7. Lu ZH, Ma JW, Liu B, et al. Hyperbaric oxygen therapy sensitizes ninstimute treatment for glioma in mice. Cancer Med, 2016; 5: 3147-3155.
8. Chen YL, Zhang YN, Wang ZZ, et al. Effects of adenosine metabolism in astrocytes on central nervous system oxygen toxicity. Brain Res, 2016; 1635: 180-189.
9. Song X, Feng L, Liang C, et al. Ultrasound Triggered Tumor Oxygenation with Oxygen-Shuttle Nanoperfluorocarbon to Overcome Hypoxia-Associated Resistance in Cancer Therapies. Nano Lett, 2016; 16: 6145-6153.
10. Yang G, Xu L, Chao Y, et al. Hollow MnOx: as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun, 2017; 8: 902.
11. Huang CC, Chia WT, Chung MF, et al. An Implantable Depot That Can Generate Oxygen in Situ for Overcoming Hypoxia-Induced Resistance to Anticancer Drugs in Chemotherapy. J Am Chem Soc, 2016; 138: 5222-5225.
12. Luo Z, Tian H, Liu L, et al. Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-damped chemotherapy and photodynamic therapy at a single dose. Theranostics, 2018; 8(13):3548-3596.
13. Liu MX, Gan LH, Chen LH, et al. A novel liposome-encapsulated hemoglobin/silica nanoparticle as an oxygen carrier. Int J Pharm, 2012; 427: 354-357.
14. Li TH, Jing XB, Huang YB. Polymer/Hemoglobin Assemblies: Biodegradable Oxygen Carriers for Artificial Red Blood Cells. Macromol Biosci, 2011; 11: 865-874.
15. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release, 2008; 132: 171-183.
16. Jeong H, Huh M, Lee SJ, et al. Photosensitizer-Conjugated Human Serum Albumin Nanoparticles for Effective Photodynamic Therapy. Theranostics, 2011; 1: 230-239.
17. Desai N. Challenges in Development of Nanoparticle-Based Therapeutics. AAPS J, 2012; 14: 282-295.
18. Elsadek B, Kratz F. Impact of albumin on drug delivery-New applications on the horizon. J Control Release, 2012; 157: 4-28.

http://www.thno.org